Tolebrutinib Versus Placebo in Non-relapsing Secondary Progressive Multiple Sclerosis: Efficacy and Safety Results from the Phase 3 HERCULES Trial (PL5.003)
To report the results of a phase 3 trial evaluating the efficacy and safety of tolebrutinib versus placebo in non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Authors
- Gavin Giovannoni (ORCID: https://orcid.org/0000-0001-9995-1700)
- Wendy Vargas (ORCID: https://orcid.org/0000-0001-8512-048X)
- Daniel S. Reich (ORCID: https://orcid.org/0000-0002-2628-4334)
- Patrick Vermersch (ORCID: https://orcid.org/0000-0003-0997-8817)
- Anthony Traboulsee (ORCID: https://orcid.org/0000-0002-0351-9639)
- Erik Wallstroem
- Robert Fox (ORCID: https://orcid.org/0000-0002-0950-3865)
- Amit Bar‐Or (ORCID: https://orcid.org/0000-0001-7179-0335)
- Timothy J. Turner (ORCID: https://orcid.org/0000-0001-9770-2647)
- Ye Li (ORCID: https://orcid.org/0000-0002-8647-384X)
- Sana Syed
- Celia Oreja‐Guevara
Institutions
- National Institutes of Health (US)
- Cleveland Clinic (US)
- University of British Columbia (CA)
- Inserm (FR)
- Queen Mary University of London (GB)
- Université de Lille (FR)
- Hospital Clínico San Carlos (ES)
- Centre Hospitalier Universitaire de Lille (FR)
- Sanofi (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210618
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00